STOCK TITAN
  1. Home
  2. News
  3. GOVX

Geovax Labs Inc - GOVX STOCK NEWS

Welcome to our dedicated news page for Geovax Labs (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geovax Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geovax Labs's position in the market.

News
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
Rhea-AI Summary
GeoVax Labs presents Phase 1/2 clinical trial data for gene therapy candidate Gedeptin at AACR and AHNS conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
clinical trial
-
News
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
Rhea-AI Summary
GeoVax Labs, Inc. announces that its gene therapy candidate, Gedeptin®, will be presented at the American Association for Cancer Research and American Head and Neck Society joint conference. The abstract focuses on a Phase 1/2 study of Ad/PNP with fludarabine for the treatment of head neck squamous cell carcinoma (HNSCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
News
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
Rhea-AI Summary
GeoVax Labs, Inc. announces the publication of an article on the development of a next-generation COVID-19 vaccine. The vaccine, GEO-CM04S1, is designed to induce both antibody and T cell responses to non-variable parts of the virus, providing protection against emerging variants. Initial data shows promising immune responses in patients with reduced immune system function. The vaccine is currently being tested in Phase 2 clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
News
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
partnership
-
News
GeoVax to Participate in Upcoming Industry Meetings
Rhea-AI Summary
GeoVax Labs, Inc. announced that its Chief Medical Officer will participate in the ASCO Annual Meeting and its Chairman and CEO, along with other senior management, will participate in the BIO International Convention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.67%
Tags
conferences
-
News
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
Rhea-AI Summary
GeoVax Labs presents updates on its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including positive preliminary data from an ongoing Phase 2 clinical trial. The vaccine shows high immunogenicity in patients undergoing hematological cancer treatment, supporting its progression in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.16%
Tags
covid-19
News
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences covid-19
-
News
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences
-
News
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
Rhea-AI Summary
GeoVax Labs, Inc. announces financial results for Q1 2023 and recent corporate highlights. The company is advancing its cancer gene therapy program and next-generation COVID-19 vaccine in Phase 2 clinical trials. Positive initial data was presented for the COVID-19 vaccine during the World Vaccine Congress. GeoVax has also made progress in developing a high-yield, high-capacity avian cell line system for manufacturing its vaccines. The company expanded its rights under its license agreement with City of Hope, granting it development and commercialization rights against orthopoxviruses. GeoVax reported a net loss of $4,037,916 for Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
earnings
News
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
conferences
Stock GOVX logo
Geovax Labs Inc

Nasdaq:GOVX

GOVX Rankings

N/A Ranked by Market Cap
#4578 Ranked by Stock Gains
N/A Ranked by Dividends

GOVX Stock Data

3.71M
1.89M
1.69%
15.73%
0.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Smyrna

About GOVX

geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.